IRIS
BALLESTRERO, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 21.675
Totale 21.675
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 21.675
Totale 21.675
Salva come PNG Salva come JPEG
Città #
Genova 15.298
Rapallo 2.675
Genoa 2.419
Vado Ligure 1.228
Bordighera 55
Totale 21.675
Salva come PNG Salva come JPEG
Nome #
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. 206
High frequency of trisomy 8 in acute promyelocytic leukemia: a fluorescence in situ hybridization study. 178
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of AKT-mediated gene repression 178
1222 POSTER Chemical Screening for Potentiators of Lapatinib Activity in Human Breast Cancer 177
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry 176
1221 POSTER Chemical-genetic Screenings for Synthetic-lethal Interactions in Breast Cancer 175
P-334 * Radiological assessments for select patients in neoadjuvant setting in rectal cancer: monoinstitutional experience 173
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 173
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair. 167
Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast carcinoma cell contamination. 167
Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics 163
Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. 160
Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies. 160
Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors. 158
APO866 activity in hematologic malignancies: a preclinical in vitro study. 157
DNA aneuploidy relationship with patient age and tobacco smoke in OPMDs/OSCCs 154
5-fluorouracil causes endothelial cell senescence: Potential protective role of glucagon-like peptide 1 153
Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial 153
Ras-induced resistance to lapatinib is overcome by MEK inhibition 149
Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. 149
Discovery of novel and selective SIRT6 inhibitors. 148
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. 148
Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. 147
A multi-scale approach to colorectal cancer: from a biochemical- interaction signaling-network level, to multi-cellular dynamics of malignant transformation. Interplay with mutations and onco-protein inhibitor drugs. 147
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia 147
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation 146
Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes. possible relevance to the assays for the detection of micrometastatic breast cancer 145
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 144
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 143
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients 143
Uncovering the genomic heterogeneity of multifocal breast cancer 141
Sirt6 regulates dendritic cell differentiation, maturation, and function 140
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società  Italiana di Medicina Interna) Study 140
Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. 140
Lymph node number, surface area and lymph node ratio are important prognostic indicators in neoadjuvant chemoradiotherapy treated rectal cancer 140
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 139
Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. 138
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. 138
Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF 135
Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. 135
Abstract 49: Agreement of immunohistochemistry, fluorescence in situ hybridization, real-time quantitative polymerase-chain reaction, and quantitative reverse transcriptase PCR for Her-2/Neu status assessment in breast cancer patients: a single center, retrospective m 134
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma 133
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. 133
Fasting potentiates the anticancer activity of tyrosin kinase inhibitors by strenghtening MAPK signalling inhibition. 132
Squalene epoxidase as a promising metabolic target in cancer treatment 132
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 132
Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations 132
HMGA2 overexpression in plycythemia vera with t(12;21) (q14;q22) 132
Parameter Space Exploration within Dynamic Simulations of Signaling Networks 131
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition 131
A new human calpastatin skipped of the inhibitory region protects calpain-1 from inactivation and degradation 130
Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer 129
Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin. 128
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 128
High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule 124
Platelets as scavengers of neutrophil-derived oxidants: a possible defence mechanism at sites of vascular injury. 124
Germline mutations in the von Hippel-Lindau gene in Italian patients. 123
Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. 122
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. 122
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 122
Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments. Concordance with experimental results. 122
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma 121
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 121
Standard-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) allows safe and repeated administration of high-dose cyclophosphamide, etoposide and cisplatin (CEP) 120
Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. 120
Chemical-genetic Screenings for Synthetic-lethal Interactions in Breast Cancer 120
Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer 120
Tumor cell lysis by activated human neutrophils: analysis of neutrophil-delivered oxidative attack and role of leukocyte function-associated antigen 1. 119
Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer. 119
Protective effects of carvedilol against doxorubicin-induced apoptosis in cardiac muscle cells 119
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 118
Immunotherapy with dendritic cells for cancer 118
Nicotinamide Phosphoribosyltransferase As A Target In Inflammation-Related Disorders. 118
Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer 118
Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions. 118
Dynamic Simulations of Pathway Cross-talks Relevant in Colorectal Cancer: A Quantitative Parameter Sensitivity Analysis 117
The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer. 117
The use of dendritic cells in cancer immunotherapy. 117
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial 117
Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer 116
The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level 115
The proteasome and its inhibitors in immune regulation and immune disorders. 114
Polypharmacy in older people: Lessons from 10 years of experience with the REPOSI register 114
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. 113
Monocyte-derived macrophages as helper cells in monocyte-mediated cytolysis. 112
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 112
Activation of the death receptor apoptosis pathway by TRAIL overcomes anticancer drug resisitance in antiapoptotic bcl-2 family members expressing lymphoma cells 111
Molecular characterization of an Italian series of sporadic GISTs. 111
Rejuvenating sirtuins: the rise of a new family of cancer drug targets 111
Reliability and reproducibility of a RNA preamplification method for low-density array analysis from formalin-fixed paraffin-embedded breast cancer samples. 110
Autologous peripheral blood stem cells (PBSC) in breast cancer. 110
Augmentation of neutrophil-mediated erythrocyte lysis by cells derived in vitro from human monocytes. 110
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases 110
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis 109
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 109
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. 109
DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. 108
Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. 108
Circulating tumor DNA using tagged targeted deep sequencing to assess minimal residual disease in breast cancer patients undergoing neoadjuvant chemotherapy 108
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. 107
Totale 13.330
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.265
article - articoli 67.122
book - libri 0
conference - conferenze 1.411
curatela - curatele 0
other - altro 0
patent - brevetti 112
selected - selezionate 0
volume - volumi 620
Totale 138.530
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.669 0 0 0 0 516 621 925 443 517 873 584 190
2020/20211.797 120 164 97 164 158 117 87 173 155 225 191 146
2021/20222.717 94 185 154 366 142 212 180 538 153 239 139 315
2022/20233.224 289 297 23 360 558 484 31 237 479 18 392 56
2023/20241.835 71 213 39 245 150 314 102 156 88 48 111 298
2024/20251.368 204 314 164 402 284 0 0 0 0 0 0 0
Totale 22.136